TABLE 4.
Association between health outcomes and exposure to silica (yes vs. no).
| Unadjusted OR (95% CI) |
Adjusted OR (95% CI) |
Unadjusted β (95% CI) |
Adjusted β (95% CI) |
|
| ILD (yes vs. no) (N = 1,371)a | 1.44 (0.94–2.23) | 1.21 (0.73–1.99) | – | – |
| Severe ILD* (vs. mild ILD) (N = 370)b | 1.60 (0.74–3.50) | 2.05 (0.96–5.36) | – | – |
| Diffuse disease (yes vs. no) (N = 1,397)c | 1.95 (1.28–2.99) | 1.54 (0.99–2.42) | – | – |
| GI-14 (N = 1,397)d | – | – | 0.85 (0.19–1.51) | 0.67 (-0.03–1.36) |
| ATA (yes vs. no) (N = 1,222)e | 1.54 (0.89–2.66) | 1.47 (0.82–2.64) | – | – |
| ACA (yes vs. no) (N = 1,222)f | 0.60 (0.37–0.98) | 0.76 (0.45–1.29) | – | – |
| Earlier age of onset of disease ≥ 50 years (N = 1,395)g | 0.53 (0.33–0.84) | 0.47 (0.29–0.77) | – | – |
| Age of onset of Raynauds ≥ 50 years (N = 1,397)h | 0.53 (0.33–0.85) | 0.48 (0.29–0.78) | – | – |
aModel adjusted for age, sex, diffuse disease, immunosuppressive medication, disease duration, ethnicity, smoking and organic solvents.
bModel adjusted for age, sex, diffuse disease, immunosuppressive medication, disease duration, ethnicity, smoking and organic solvents.
cModel adjusted for age, sex, smoking, and ethnicity.
dModel adjusted for age, sex, disease duration, diffuse disease, immunosuppressive medication, smoking and organic solvents.
eModel adjusted for age, sex, smoking, and ethnicity.
fModel adjusted for age, sex, smoking, and ethnicity.
gModel adjusted for sex, smoking, ethnicity, and diffuse disease.
hModel adjusted for sex, smoking, ethnicity, and diffuse disease. *Defined as presence of ILD and FVC < 70. ILD, interstitial lung disease; ACA, anticentromere antibody; ATA, anti-topoisomerase I antibody. Bold indicates statistically significant values.